THU0228 Tofacitinib, an Oral Janus Kinase Inhibitor: Post-HOC Analyses of Efficacy and Safety of Monotherapy Versus Combination Therapy in a Phase 3 Rheumatoid Arthritis Population

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A242.1-A242
Author(s):  
E. Keystone ◽  
R. Fleischmann ◽  
R. van Vollenhoven ◽  
J. Kremer ◽  
D. Gruben ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Combination Therapy ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Janus Kinase Inhibitor ◽  
Rheumatoid Arthritis Population ◽  
Post Hoc

Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies

2019 ◽  
Vol 15 (1) ◽  
pp. 43-53
Author(s):  
Ruben Burgos-Vargas ◽  
Mario Cardiel ◽  
Daniel Xibillèc) ◽  
Cèc)sar Pacheco-Tena ◽  
Virginia Pascual-Ramos ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Janus Kinase Inhibitor

scholarly journals Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population

2018 ◽  
Vol 5 (2) ◽  
pp. 383-401 ◽  
Author(s):  
Stephen Hall ◽  
Peter Nash ◽  
Maureen Rischmueller ◽  
David Bossingham ◽  
Paul Bird ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Efficacy And Safety ◽  
Janus Kinase Inhibitor ◽  
Rheumatoid Arthritis Population

Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies

2019 ◽  
Vol 15 (1) ◽  
pp. 43-53
Author(s):  
Ruben Burgos-Vargas ◽  
Mario Cardiel ◽  
Daniel Xibillé ◽  
César Pacheco-Tena ◽  
Virginia Pascual-Ramos ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Janus Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document